135 related articles for article (PubMed ID: 2204450)
1. Thalidomide in the treatment of graft-versus-host disease.
Heney D; Bailey CC; Lewis IJ
Biomed Pharmacother; 1990; 44(4):199-204. PubMed ID: 2204450
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation.
McCarthy DM; Kanfer EJ; Barrett AJ
Biomed Pharmacother; 1989; 43(9):693-7. PubMed ID: 2696566
[TBL] [Abstract][Full Text] [Related]
3. The use of thalidomide in chronic refractory graft versus host disease.
van de Poel MH; Pasman PC; Schouten HC
Neth J Med; 2001 Aug; 59(2):45-9. PubMed ID: 11476911
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation.
Cole CH; Rogers PC; Pritchard S; Phillips G; Chan KW
Bone Marrow Transplant; 1994 Dec; 14(6):937-42. PubMed ID: 7711671
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature.
Mehta P; Kedar A; Graham-Pole J; Skoda-Smith S; Wingard JR
Pediatrics; 1999 Apr; 103(4):e44. PubMed ID: 10103336
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide for the treatment of chronic graft-versus-host disease.
Vogelsang GB; Farmer ER; Hess AD; Altamonte V; Beschorner WE; Jabs DA; Corio RL; Levin LS; Colvin OM; Wingard JR
N Engl J Med; 1992 Apr; 326(16):1055-8. PubMed ID: 1549151
[TBL] [Abstract][Full Text] [Related]
7. Severe cutaneous ulceration following treatment with thalidomide for GVHD.
Schlossberg H; Klumpp T; Sabol P; Herman J; Mangan K
Bone Marrow Transplant; 2001 Jan; 27(2):229-30. PubMed ID: 11281398
[TBL] [Abstract][Full Text] [Related]
8. Response to thalidomide therapy in refractory chronic graft-versus-host disease.
Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NK; Wagner J; Enright H
Bone Marrow Transplant; 2000 Oct; 26(8):865-9. PubMed ID: 11081386
[TBL] [Abstract][Full Text] [Related]
9. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children.
Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasciulli A; Vassallo E; Miniero R; Uderzo C
Bone Marrow Transplant; 1998 Mar; 21(6):577-81. PubMed ID: 9543061
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide responsive chronic pulmonary GVHD.
Forsyth CJ; Cremer PD; Torzillo P; Iland HJ; Young GA
Bone Marrow Transplant; 1996 Feb; 17(2):291-3. PubMed ID: 8640183
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide back in good graces--seems to help GVHD patients.
Oncology (Williston Park); 1988 Sep; 2(9):29. PubMed ID: 3275064
[No Abstract] [Full Text] [Related]
12. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide for treatment of graft-versus-host disease.
Vogelsang GB; Hess AD; Santos GW
Bone Marrow Transplant; 1988 Sep; 3(5):393-8. PubMed ID: 3056547
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide as therapy for intestinal chronic GVHD.
Lopez J; Ulibarrena C; Garcia-Laraña J; Odriozola J; Pérez de Oteyza J; Sastre JL; Navarro JL
Bone Marrow Transplant; 1993 Mar; 11(3):251-2. PubMed ID: 8467293
[No Abstract] [Full Text] [Related]
15. Graft-versus-host disease.
Bron D
Curr Opin Oncol; 1994 Jul; 6(4):358-64. PubMed ID: 7803536
[TBL] [Abstract][Full Text] [Related]
16. [Sclerodermatous cutaneous reaction of graft vs host disease treated with thalidomide].
Pédailles S; Troussard X; Launay V; Bazin A; Sentias C; Surbled M
Presse Med; 1993 Jan 2-16; 22(1):37. PubMed ID: 8469665
[No Abstract] [Full Text] [Related]
17. Ocular graft-versus-host disease: a review.
Shikari H; Antin JH; Dana R
Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
[TBL] [Abstract][Full Text] [Related]
18. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
[TBL] [Abstract][Full Text] [Related]
19. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model.
Vogelsang GB; Hess AD; Gordon G; Santos GW
Transplantation; 1986 May; 41(5):644-7. PubMed ID: 2939610
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
Chao NJ; Parker PM; Niland JC; Wong RM; Dagis A; Long GD; Nademanee AP; Negrin RS; Snyder DS; Hu WW; Gould KA; Tierney DK; Zwingenberger K; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1996 May; 2(2):86-92. PubMed ID: 9118303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
